A U.S.-based biotechnology company named Bluebird bio announced in September 2021 that its beti-cel gene therapy had been formally submitted for approval in the U.S. to treat beta-thalassemia. As a one-time treatment for beta-thalassemia, Beta-thalassemia (B-thal) Market a rare condition that impairs the production of haemoglobin, the oxygen-carrying protein in red blood cells, beti-cel was examined in numerous early- and late-stage clinical trials.
The Food and Drug Administration has received a letter of approval from Bluebird Bio, a biopharmaceutical company, for its therapy for beta-thalassemia patients who require frequent red blood cell transfusions. Beti-cel is currently legal for sale in Europe under the trade name Zynteglo.
Read More:
https://knackersblogger.blogspot.com/2022/11/beta-thalassemia-b-thal-market-size.html
Comments
0 comment